Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Appendix Cancer: early-phase trial registry
3 of 7 indexed Appendix Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Appendix Cancer: 7 US clinical trials tracked, 3 recruiting.
Appendix Cancer is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Andreana Holowatyj, PhD, MSCI, running 1 of these trials.
Enrollment posture brief
Registry condition appendix-cancer
OPEN 3 | RECR 43% | LATE 0 | EARLY 3 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)
Appendix Cancer lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Appendix Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Appendix Cancer is recruiting below its size-band peers.
3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Appendix Cancer trials is spread across many organizations.
Andreana Holowatyj, PhD, MSCI accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Appendix Cancer enrolment sits around 130 participants.
Median target enrolment is 130 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
Appendix Cancer research is mostly interventional.
5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Genetics of Appendix Cancer Study
Andreana Holowatyj, PhD, MSCI
NCT05734430
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Dartmouth-Hitchcock Medical Center
NCT05780684
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
Memorial Sloan Kettering Cancer Center
NCT01815359
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04902872
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
University of Chicago
NCT04157322
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
University of Massachusetts, Worcester
NCT02833753
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Appendix Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Appendix Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Appendix Cancer page
7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Appendix Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Andreana Holowatyj, PhD, MSCI sponsors the most Appendix Cancer trials on record, review their full trial history before evaluating a specific study. See Andreana Holowatyj, PhD, MSCI's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Appendix Cancer condition card totals 7 registered trials; most-linked intervention prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.